Synthesis of Novel Acetyl-11-keto-β-boswellic Acid Derivatives as Potential Anti-GBM Agents

© 2024 Wiley‐VHCA AG, Zurich, Switzerland..

Acetyl-11-keto-β-boswellic acid (AKBA) is known to inhibit the growth of glioblastoma (GBM) cells and subcutaneous GBM. A series of acetyl-11-keto-β-boswellic acid (AKBA) derivatives containing the oxime-ester functionality or amide side chains were synthesized, and their anti-GBM activities were evaluated. Some of these compounds exhibited significant inhibitory activity against cell proliferation in U87 and U251 GBM cell lines, with IC50 values in the micromolar concentration range. Cellular thermal shift analysis showed that A-01 and A-10 improved the thermal stability of FOXM1, indicating that these highly active compounds may directly bind to FOXM1 in cells. Docking studies of the two most active compounds, A-01 and A-10, revealed key interactions between these compounds and the active site of FOXM1, in which the amide moiety at the C-24 position was essential for improving the activity. These results suggested that A-10 is a suitable lead molecule for the development of FOXM1 inhibitors. Thus, the rational design of AKBA derivatives with amide side chains holds significant potential for discovering of a new class of triterpenoids capable of inhibiting GBM cell proliferation.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:21

Enthalten in:

Chemistry & biodiversity - 21(2024), 4 vom: 01. Apr., Seite e202301979

Sprache:

Englisch

Beteiligte Personen:

Sun, Mingxia [VerfasserIn]
Zhang, Sen [VerfasserIn]
Wang, Jinhua [VerfasserIn]
Du, Guanhua [VerfasserIn]
Ji, Tengfei [VerfasserIn]

Links:

Volltext

Themen:

16VY3TM7ZO
AKBA derivatives
Acetyl-11-ketoboswellic acid
Amides
Antiglomerular basement membrane antibody
Antineoplaston A10
Autoantibodies
Benzeneacetamides
FOXM1
GBM
Journal Article
Piperidones
Triterpenes

Anmerkungen:

Date Completed 18.04.2024

Date Revised 18.04.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1002/cbdv.202301979

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM367921936